Core Insights - Oragenics, Inc. is focused on developing novel intranasal therapies for brain-related disorders, particularly its lead candidate ONP-002 for mild traumatic brain injury (mTBI) [1][4] - The company participated in the 3rd Nasal Formulation & Delivery Summit, highlighting its commitment to innovation in non-invasive CNS therapeutics [1][3] Company Developments - Dr. James Kelly, Chief Medical Officer of Oragenics, shared insights on optimizing intranasal drug delivery and its advantages in neurological treatment during the summit [2] - ONP-002 is designed for rapid absorption and targeted brain delivery through intranasal administration, aiming to improve outcomes for concussion patients [3][4] Industry Context - The summit gathered industry leaders to discuss innovations in intranasal drug delivery, focusing on CNS therapeutics, emergency-use treatments, and infectious disease applications [2]

Core Viewpoint - Polyrizon Ltd. has signed a non-binding Letter of Intent with a biotech company focused on psychedelic-derived therapeutics to develop a novel intranasal formulation for psychedelic-based treatment applications [1][2]. Group 1: Collaboration Details - The agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments, emphasizing the potential of intranasal drug delivery in enhancing bioavailability, efficacy, and patient accessibility [2][4]. - Polyrizon will lead the formulation's development using its mucoadhesive drug delivery technology, while the psychedelic company will fund the research and development process, including feasibility studies [4]. Group 2: Technology and Innovation - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier in the nasal cavity to protect against viruses and allergens [5]. - The company's proprietary Capture and Contain (C&C) hydrogel technology aims to improve bioadhesion and prolonged retention at the nasal deposition site for drug delivery [5]. Group 3: Future Prospects - If the collaboration is successful, it could lead to further clinical development and commercialization, with plans to negotiate a definitive agreement outlining intellectual property ownership, commercialization rights, and financial terms [4]. - Polyrizon is expected to receive royalty payments for any future commercialization of the product by the psychedelic company [4].